Human α-galactosidase,αGAL ELISA Kit
-
中文名稱:人α半乳糖苷酶(αGAL)酶聯(lián)免疫試劑盒
-
貨號:CSB-E09457h
-
規(guī)格:96T/48T
-
價格:¥3600/¥2500
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:人α半乳糖苷酶(αGAL)酶聯(lián)免疫試劑盒(CSB-E09457h)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的GLA含量。GLA即α-半乳糖苷酶A,相關(guān)背景上,其缺陷會引發(fā)法布里病。在研究機(jī)制方面,主要探索補(bǔ)充該酶的治療方式,通過提供外源性GLA改善機(jī)體代謝,減輕因底物蓄積造成的多器官損害,為法布里病治療帶來希望。試劑盒檢測范圍為7.8 pg/mL-500 pg/mL,該產(chǎn)品適用于法布雷病機(jī)制研究、溶酶體貯積癥模型構(gòu)建、藥物干預(yù)效果評價等科研領(lǐng)域本品僅用于科研,不用于臨床診斷,產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
-
別名:AGAL_HUMAN ELISA Kit; Agalsidase alfa ELISA Kit; Alpha D galactosidase A ELISA Kit; Alpha D galactoside galactohydrolase 1 ELISA Kit; Alpha D galactoside galactohydrolase ELISA Kit; Alpha gal A ELISA Kit; Alpha galactosidase A ELISA Kit; Alpha-D-galactosidase A ELISA Kit; Alpha-D-galactoside galactohydrolase ELISA Kit; Alpha-galactosidase A ELISA Kit; GALA ELISA Kit; Galactosidase; alpha ELISA Kit; GLA ELISA Kit; GLA protein ELISA Kit; Melibiase ELISA Kit
-
縮寫:
-
Uniprot No.:
-
種屬:Homo sapiens (Human)
-
樣本類型:serum, plasma, tissue homogenates
-
檢測范圍:7.8 pg/mL-500 pg/mL
-
靈敏度:1.95 pg/mL
-
反應(yīng)時間:1-5h
-
樣本體積:50-100ul
-
檢測波長:450 nm
-
研究領(lǐng)域:Cardiovascular
-
測定原理:quantitative
-
測定方法:Sandwich
-
精密度:
Intra-assay Precision (Precision within an assay): CV%<8% Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision (Precision between assays): CV%<10% Three samples of known concentration were tested in twenty assays to assess. -
線性度:
To assess the linearity of the assay, samples were spiked with high concentrations of human αGAL in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. Sample Serum(n=4) 1:100 Average % 86 Range % 81-92 1:200 Average % 92 Range % 87-96 1:400 Average % 84 Range % 81-86 1:800 Average % 102 Range % 100-106 -
回收率:
The recovery of human αGAL spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. Sample Type Average % Recovery Range Serum (n=5) 94 90-98 EDTA plasma (n=4) 88 84-93 -
標(biāo)準(zhǔn)曲線:
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. pg/ml OD1 OD2 Average Corrected 500 2.420 2.451 2.436 2.272 250 2.065 2.107 2.086 1.922 125 1.663 1.705 1.684 1.520 62.5 1.165 1.183 1.174 1.010 31.2 0.735 0.788 0.762 0.598 15.6 0.482 0.499 0.491 0.327 7.8 0.328 0.341 0.335 0.171 0 0.162 0.166 0.164 -
數(shù)據(jù)處理:
-
貨期:3-5 working days
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能:Catalyzes the hydrolysis of glycosphingolipids and participates in their degradation in the lysosome.
-
基因功能參考文獻(xiàn):
- GLA variants found included R118C (n = 2), D83N, and D313Y (n = 7); IVS6-22 C>T, IVS4-16 A>G, IVS2+990C>A, 5'UTR-10 C>T (n = 4), IVS1-581 C>T, IVS1-1238 G>A, 5'UTR-30 G>A, IVS2+590C>T, IVS0-12 G>A, IVS4+68A>G, IVS0-10 C>T, IVS2-81-77delCAGCC, IVS2-77delC. We found that patients with common heart disease did not contain a substantial number of patients with undiagnosed Fabry disease. PMID: 29227985
- GLA DNA screening protocols starting from the dialysis population and upstream extended to families of affected individuals may be an effective strategy to maximize the early identification of subjects with Fabry disease. PMID: 30099469
- family study with the classical phenotype of Fabry disease due to the novel nonsense mutation c.607G>T (p.E203X) of the GLA gene; the Fabry disease phenotype is highly variable in heterozygote females, even within the same family PMID: 28152533
- It negatively regulates calcification of human aortic valve interstitial cells. PMID: 29653899
- Results from a study on gene variability markers in early-stage human embryos shows that GLA is a putative variability marker for the 3-day, 8-cell embryo stage. PMID: 26288249
- Presence of isolated heterozygous -10C >T SNP is not associated with clinically relevant symptoms or organ manifestations as seen in Fabry disease. PMID: 29794742
- The D313Y variant in the GLA gene was not Fabry disease causative in 2 Danish families. PMID: 29037082
- The mutation p.D313Y in the GLA gene may lead to organ manifestations and elevation of the Fabry-specific biomarker lyso-globotriaosylsphingosine. PMID: 28276057
- Four novel GLA pathogenic mutations are reported and evidence of pathogenicity of the D313Y mutation is provided. PMID: 28988177
- alpha-Galactosidase A genotype N215S does not lead to the development of a classical Fabry phenotype but induces a specific cardiac variant of Fabry disease mimicking nonobstructive hypertrophic cardiomyopathy. PMID: 29018006
- GLA c.196G>C variant is a genetic risk factor for cerebral small-vessel occlusion and non-cardioembolism in Japanese males but not in females. PMID: 28275245
- we presented the clinical characters of a Chinese FD pedigree mimicking familial episodic pain. Furthermore, our finding suggests that a novel double mutation of GLA (c.273_276del TGAT in cis with c.281G>T) is associated with FD PMID: 27531472
- Results showed that most Fabry disease patients carrying GLA IVS4+919A did not show abnormal cardiac phenotypes. The near-absence of GLA IVS4+919A in heart disease cohort suggested that this variant is not a frequent cause of overt heart diseases in Taiwan. PMID: 28377241
- This longitudinal Fabry Registry study analyzed data from patients with Fabry disease to determine the incidence and type of severe clinical events following initiation of enzyme replacement therapy (ERT) with agalsidase beta, as well as risk factors associated with occurrence of these events PMID: 27510433
- alpha-galactosidase A mutation, IVS4-type Fabry disease has features similar to those of classic Fabry disease and a higher frequency of deep white matter hyperintensities and a higher incidence of infarctions and pulvinar signs than in healthy controls PMID: 26869469
- We demonstrate that the wild-type sequence harbors an hnRNP A1 and hnRNP A2/B1-binding exonic splicing silencer (ESS) overlapping the 5'splice site (5'ss) that prevents pseudoexon inclusion.we demonstrate that splice switching oligonucleotide (SSO) mediated blocking of the pseudoexon 3'ss and 5'ss effectively restores normal GLA splicing PMID: 27595546
- Four patients had non-amenable mutant forms of a-Gal based on the validated cell-based assay conducted after treatment initiation and were excluded from primary efficacy analyses only. PMID: 27834756
- Mesenchymal stem cells with reduced GLA activity are prone to apoptosis and senescence due to impaired autophagy and DNA repair capacity. PMID: 28098348
- we review the various types of GLA variants and recommend that pathogenicity be considered only when associated with elevated globotriaosylceramide in disease-relevant organs and tissues as analyzed by mass spectrometry. PMID: 27195818
- findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future PMID: 28430823
- Results found a novel heterozygous stop codon mutation in exon 1 of the GLA gene in female patients with Fabry Disease with methylation in the non-mutated allele thought to be associated with the clinical severity of the disease. PMID: 28087245
- Study described the demographic data, wide clinical spectrum of phenotypes, and GLA mutation spectrum of Fabry disease in Korea. Most of the patients had classical Fabry disease, with a 4 times higher incidence than that of late-onset Fabry disease, indicating an underdiagnosis of mild, late-onset Fabry disease. PMID: 28723748
- we reviewed other small molecules that were reported to have a stabilizing effect on some GLA missense mutations in vitro and might be developed to act in synergy or as an alternative to 1-deoxygalactonojirimycin PMID: 27916943
- No pathogenic mutations in the coding regions of the GLA gene were identified in this group of patients and thus no Fabry disease was found in this study. PMID: 26981927
- High desphospho-uncarboxylated matrix Gla protein level, reflecting a poor vitamin K status, seems to be associated with kidney damage and may be also a marker of cardiovascular risk in CKD patients PMID: 27100101
- Similar central nervous system manifestations in patients with the IVS4 mutation or classical Fabry mutations. PMID: 28166746
- Case Report: Kidney transplantation from a mother with unrecognized Fabry disease to her son with low alpha-galactosidase A activity. PMID: 26971403
- p.M187R GLA mutation in Fabry disease causes a severe systemic and ophthalmologic phenotype, in both male and female patients. PMID: 28225726
- The results of the current study suggest that the GLA haplotype D313Y does not lead to severe organ manifestations as seen in genotypes known to be causal for classical Fabry disease. PMID: 27059467
- We report a case of Fabry disease with a p.R301X (c.901 C>T) mutation in a 39-year-old man who was being treated for chronic sclerosing glomerulonephritis for 2 years. Family screening tests showed that the proband's mother, sister, and daughter had the same mutation with different phenotypes. PMID: 27156739
- Case Report: hypertrophic obstructive cardiomyopathy with Fabry disease with the GLA E66Q mutation. PMID: 27160240
- We conclude that a mild GLA variant is typically characterized by high residual enzyme activity and normal biomarker levels. We found evidence that these variants can still be classified as a distinctive, but milder, sub-type of FD. PMID: 26415523
- Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for alpha-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy. PMID: 26564084
- Study describes 5 novel mutations found in the GLA gene of patients with clinical diagnosis of Fabry disease. PMID: 26691501
- The present study confirms the heterogeneity of mutations in Fabry disease and the importance of molecular analysis for genetic counseling, female heterozygotes detection as well as therapeutic decisions. PMID: 26297554
- GLA gene variations correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma PMID: 26070511
- results directly implicated the GLA mutation p.E66Q as the genetic etiology of the Chinese renal variant FD pedigree. PMID: 26456105
- This study indicated that the p.E66Q variant of GLA does not affect the progression of chronic kidney disease. PMID: 24718812
- Thus, inheritance of the CIH caused an mRNA deregulation altering the GLA expression pattern, producing a tissue glycolipid storage. PMID: 26334996
- data strongly suggest that the GLA p.(Arg118Cys) variant does not segregate with Fabry disease clinical phenotypes in a Mendelian fashion, but might be a modulator of the multifactorial risk of cerebrovascular disease PMID: 25468652
- In Fabry disease patients, the alpha-galactosidase A-10T allele appears to be causal for neurological manifestations. PMID: 25423912
- Some clinical cases of some members of a Sicilian family to express phenotypical variability of Anderson-Fabry disease in subjects with the same genetic mutation in alpha galactosidase A gene, are reported. PMID: 25281798
- Case Report: immunohistologically detected synaptopodin upregulation in foamy podocytes in Fabry disease due to novel alpha-galactosidase A mutation. PMID: 25295576
- These data confirmed that the specific approach can effectively contribute to the identification of pathological mutations in GLA. PMID: 25382311
- The novel mutation p.M187R/g7219 T>G is associated with a particularly malignant cardiac phenotype in males and females over 40 years. PMID: 24679964
- OC follows a gene duplication strategy while MGP variability was obtained mostly by the use of multiple promoters and alternative splicing, leading to proteins with additional functional characteristics and alternative gene regulatory pathways. [review] PMID: 25068814
- It is clear that a certain intronic haplotype in males with cryptogenic stroke is associated with reduced GLA expression and function. PMID: 25101867
- GLA p.E66Q mutation is a genetic risk factor for cerebral small-vessel occlusion in elderly Japanese PMID: 23724928
- residues important for expression of the GLA activity PMID: 24386359
- A Fabry disease patient and his daughter had the mutation c.493 G > C in the 3d exon of the GLA gene. D165H substitution affects protein folding. This highly conserved AA may be a key amino acid for enzyme functionality. PMID: 24398019
顯示更多
收起更多
-
相關(guān)疾?。?/div>Fabry disease (FD)亞細(xì)胞定位:Lysosome.蛋白家族:Glycosyl hydrolase 27 family數(shù)據(jù)庫鏈接:
Most popular with customers
-
Human Transforming Growth factor β1,TGF-β1 ELISA kit
Detect Range: 23.5 pg/ml-1500 pg/ml
Sensitivity: 5.8 pg/ml
-
-
-
Mouse Tumor necrosis factor α,TNF-α ELISA Kit
Detect Range: 7.8 pg/ml-500 pg/ml
Sensitivity: 1.95 pg/ml
-
-
-
-